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Abstract The effects of tamoxifen (TAM), a widely used agent in the treatment ofbreast cancer, were xamined on phospholipase D (PLD)-mediated 
phospholipid hydrolysis. In drug-sensitive MCF-7 human breast carcinoma cells TAM, similar to several well-established activators of PLD, had 
no effect on phospholipid hydrolysis. In an estrogen receptor-deficient multidrug-resistant subline of MCF-7 cells, TAM preferentially stimulated 
the hydrolysis of phosphatidylethanolamine; two-fold stimulation required 2.5 or 5/tM TAM in the absence or presence ofserum, respectively. In 
NIH 3T3 fibroblasts significant (4- to 4.8-fold) stimulation of phosphatidylethanolamine and phosphatidylcholine hydrolysis n the presence ofserum 
required 10/tM TAM. These data establish that TAM can stimulate PLD activity by an estrogen receptor-independent mechanism. 
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1. Introduction 
Tamoxifen (TAM), a triphenylethylene non-steroidal nti- 
estrogen, has been used widely and effectively for treatment of
patients with all stages of breast cancer [1-3]. While the re- 
sponse rate of estrogen receptor-positive tumors to TAM is 
higher, a relatively high percentage of estrogen receptor-nega- 
tive patients also demonstrate a response to tamoxifen [3]. This 
indicates that TAM cannot be regarded as a simple anti-estro- 
gen, which is an important consideration because development 
of initially estrogen-dependent non-metastatic breast umors to 
a more aggressive strogen-independent phenotype is almost 
inevitable. While the mechanism(s) for the estrogen-independ- 
ent growth inhibitory effect(s) of TAM is unknown, TAM has 
been shown to exert estrogen receptor-independent effects on 
the function of calmodulin [4--6] and protein kinase C (PKC) 
[7-9]. However, these latter effects required relatively high con- 
centrations of TAM which appear to be physiologically irrele- 
vant. Therefore, we have examined possible ffects of TAM on 
some other components of the signal transduction system in- 
volved in growth regulation. 
The hydrolysis of phospholipids by hormone- and phorbol 
ester-stimulated phospholipase D (PLD) results in the forma- 
tion of phosphatidic acid [I0,11]. Phosphatidic acid can serve 
as a messenger molecule with the potential to regulate cell 
growth [12-17], metastasis of tumor cells [18], exocytosis [19- 
24], as well as other cellular processes (reviewed in [25]). Con- 
sidering the emerging role of PLD in signal transduction aswell 
as the known ability of TAM to alter the physical properties 
of biological membranes [26,27], the goal of this work was to 
examine possible modification of PLD activity by TAM. TAM 
was found to stimulate the hydrolysis of both phosphatidyle- 
thanolamine (PtdEtn) and phosphatidylcholine (PtdCho) in 
NIH 3T3 fibroblasts and in a multidrug-resistant subline of 
MCF-7 human breast carcinoma cells, but not in the parent 
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MCF-7 cells, by an estrogen receptor-independent mechanism. 
The possible relevance of these findings to the effects of TAM 
on multidrug resistance and tumor growth will be discussed. 
2. Materials and methods 
2.1. Materials 
TAM, phorbol 12-myristate 13-acetate (PMA), and Dowex- 
50W(H ÷) were purchased from Sigma; [methyl-~4C]choline chloride (50 
mCi/mmol), [2-14C]ethanolamine (50 mCi/mmol) and [1-14C]palmitic 
acid (60 mCi/mmol) were from Amersham; phosphatidylethanol (PtdE- 
tOH) was from Avanti Polar Lipids Inc., and tissue culture reagents 
were purchased from Gibco. 
2.2. Cell culture 
The MCF-7 human breast cancer cell lines (drug-sensitive MCF-7/ 
WT cells and multidrug-resistant MCF-7/MDR cells) were generously 
provided by Dr. Kenneth Cowan (National Cancer Institute, NIH, 
Bethesda, MD, USA). MCF-7 cells were maintained as described ear- 
lier [28]. NIH 3T3 clone 7 fibroblasts were obtained from Dr. Douglas 
R. Lowy (National Cancer Institute, Bethesda, MD, USA) and were 
cultured continuously inDulbecco's modified Eagle's medium supple- 
mented with 10% (v/v) fetal calf serum, penicillin (50 U/ml), streptomy- 
cin (50/tg/ml) and glutamine (2 mM). 
2.3. Measurement of PtdEtOH formation in MCF-7 and NIH 3T3 cells 
Cells were grown in 6-well tissue culture dishes for 48 h to about 
70-80% confluency and labeled with [1-t4C]palmitic a id (0.3/ICi/ml) 
for the last 24 h. Cells were washed, incubated infresh medium for an 
additional 2 h (to lower the amount of unesterified labeled palmitic 
acid) and then treated with TAM and/or PMA in complete medium in 
the presence of 150 mM ethanol for 30 min at 37°C. Incubations were 
terminated by scraping the cells into 2 ml of ice-cold methanol, followed 
by rapid transfer of the methanol extract to 2 ml of chloroform. PtdE- 
tOH was separated from other phospholipids on potassium oxalate 
(1%)-impregnated Silica gel H plates (Analtech) with a solvent system 
of chloroform/methanol/acetone/acetic acid/water (50: 10: 15 : 10: 2, by 
vol). 
2.4. Labeling of cellular phospholipids with [~4C]ethanolamine and 
[~4Clcholine 
MCF-7 and NIH 3T3 cells were seeded in 150 mm-diameter plastic 
dishes and were incubated with either [2-~4C]ethanolamine (0.25/~Ci/ 
ml) or [methyl-~4C]choline (0.35/ICi/ml) for 48 h. Cells were washed 
twice and then incubated in the corresponding fresh medium for 3 h; 
this additional incubation step reduces the cellular levels of water- 
soluble ~4C-labeled precursors, which are also the products of PLD 
action, by a factor of 3- to 5-fold [29]. Cells were harvested by gentle 
scraping from 3~ dishes. After an additional 20 min incubation period 
0014-5793/94/$7.00 © 1994 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(94)01200-8 
174 Z. Kiss/FEBS Letters 355 (1994) 173-177 
(allowed for the return of slightly elevated 1,2-diacylglycerol levels to 
normal levels [30]), cells were pelleted for 7 min at 500 x g. Cells were 
resuspended in either complete medium (Figs. 1 and 2) or in serum-free 
medium (Fig. 3) and then treated with TAM in the presence of 2 mM 
ethanolamine or 20 mM choline, as appropriate; these latter com- 
pounds erved to prevent phosphorylation f newly formed [~4C]etha- 
nolamine and [~4C]choline [29,31]. Suspended and attached MCF-7/ 
MDR [28] and NIH 3T3 cells [31,32] were similarly responsive toPMA, 
sphingosine and H202 with respect to the activation of PLD, but sus- 
pended cells contained 5-10 times less background levels of 14C-labeled 
precursors. This made valuation of the effects of lower concentrations 
of TAM on phospholipid hydrolysis possible. 
2.5. Determination f water-soluble products of phospholipid hydrolysis 
Fractionation of ethanolamine and choline metabolites was 
performed on Dowex-50W(H*)-packed columns (Bio-Rad Econo col- 
umns; 1 ml bed volume) as previously described [32]. 
3. Results 
Determination of the formation of [~4C]ethanolamine and 
[~4C]choline from the respective prelabeled phospholipids rep- 
resents a more sensitive assay of PLD activity compared to 
determination f PtdEtOH formation. For this reason, the pos- 
sible effects of different concentrations of TAM on PtdEtn and 
PtdCho hydrolysis were first determined in [~4C]ethanolamine- 
and [~4C]choline-labeled MCF-7 cells. As was previously de- 
scribed in detail [28], MCF-7/WT ceils exhibited only a low level 
of PLD activity which was not enhanced by PMA, sphingosine 
or H202. Presently, TAM (2.5-50 gM) also failed to enhance 
PLD-mediated hydrolysis of either [~4C]PtdEtn or [~4C]PtdCho 
in these cells (data not shown). 
In contrast, MCF-7/MDR cells contain aPLD system which 
preferentially h drolyzes PtdEtn in the presence of PMA and 
other activators [28]. Similarly, treatment of these cells with 
5-50 pM concentrations of TAM in a 10% serum-containing 
medium caused preferential stimulation of [~4qPtdEtn hydrol- 
ysis during either a 20 min (Fig. 1A) or 40 min (Fig. IB) 
incubation period. Well detectable (1.45- to 1.7-fold) stimula- 
tion of PtdEtn hydrolysis in this complete system was observed 
with 5/~M TAM, while maximal (4.25-fold) stimulation re- 
quired 50 pM TAM. 
NIH 3T3 fibroblasts contain PLD systems which hydrolyze 
both PtdEtn and PtdCho with similar efficiencies in response 
to PMA [31,32], sphingosine [33] and H20= [34]. Treatment of 
[~4C]ethanolamine- and [14C]choline-labeled NIH 3T3 fibrob- 
lasts with 10/~M TAM in 10% serum-containing medium elic- 
ited similar (1.6- to 1.65-fold) stimulatory effects on the hydrol- 
ysis of [14C]PtdEtn and [~4C]PtdCho (Fig. 2). However, higher 
(15-50 pM) concentrations of TAM preferentially stimulated 
the hydrolysis of PtdCho, so that 50 pM TAM stimulated the 
hydrolysis of PtdCho and PtdEtn 11.5- and 4.2-fold, respec- 
tively (Fig. 2). 
It is well known that TAM binds to serum proteins, thus, the 
concentration f serum in culture medium significantly affects 
the concentration-dependent inhibitory effects of TAM on cell 
growth [35,36]. For this reason, it appeared important to test 
the effect of serum on TAM-induced phospholipid hydrolysis. 
When PLD assays with MCF-7/MDR cells were performed in 
the absence of serum, TAM at a concentration as low as 2.5 
/JM stimulated the hydrolysis of [~4C]PtdEtn 1.8-fold (Fig. 3A). 
However, at higher concentrations, TAM had similar effects on 
PtdEtn hydrolysis in the absence or presence of 2 or 5% serum 
(Fig. 3A). It should be noted that these latter effects of TAM 
were also very similar to those observed in the presence of 10% 
serum (Fig. 1). In contrast, in NIH 3T3 fibroblasts 2.5--50 pM 
concentrations of TAM had only small or no effects on 
[~4C]PtdEtn hydrolysis when the assays were performed in the 
absence or presence of 2% serum (Fig. 3B). However, in the 
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Fig. 1. Concentration- and time-dependent ffects of TAM on phospholipid hydrolysis n MCF-7/MDR cells. Cells were labeled with [~4C]ethanolam- 
ine (e) or [t4C]choline (A) for 48 h, followed by treatment of suspended cells with varying concentrations (2.5-50 gM) of TAM for 20 min (A) or 
40 min (B). In each ease, the incubation medium contained 10% serum. The average 14C content of PtdEtn and PtdCho was 876,000 and 665,000 
dpm/106 cells, respectively. Each point represents the mean _+ S.E.M. of four independent i cubations. Similar esults were obtained in two other 
experiments, each performed in triplicate. 
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Fig. 2. Concentration-dependent effects of TAM on phospholipid hy- 
drolysis in NIH 3T3 fibroblasts. Cells were labeled with [~4C]etha- 
nolamine (e) or []4C]choline (&) for 48 h followed by treatment of 
suspended cells with 2.5-50 pM concentrations of TAM for 20 min. In 
each case, the incubation medium contained 10% serum. The average 
14C content of PtdEtn and PtdCho was 1.13 x 104 and 855,000 dpm/106 
cells, respectively. Each point represents he mean + S.E.M. of four 
independent i cubations. Similar results were obtained in three other 
experiments, each performed in triplicate. 
presence of 5% serum (Fig. 3B), the stimulatory effects of TAM 
on [14C]PtdEtn hydrolysis were similar, although still of a some- 
what lesser extent, than those observed in the presence of 10% 
serum (Fig. 2). In fibroblasts, ignificant stimulation ofPtdCho 
hydrolysis by TAM also required the presence of serum (data 
not shown). 
To confirm that TAM-induced phospholipid hydrolysis was 
mediated by PLD, the effect of TAM on the formation of 
PtdEtOH, which is a specific function of PLD, was also deter- 
mined. As expected, in MCF-7/WT cells 25 pM TAM had no 
effect on PtdEtOH formation, while this drug significantly en- 
hanced PtdEtOH formation both in MCF-7/MDR cells (5.9- 
fold stimulation) and NIH 3T3 fibroblasts (3.7-fold stimula- 
tion, Fig. 3). Although TAM is a reported inhibitor of PKC in 
vitro [7-9], in these experiments TAM and PMA had additive 
effects on PtdEtOH formation (Fig. 4). 
4. Discussion 
The fact that drug-sensitive breast carcinoma cells do not 
contain appreciable l vels of functional PLD ([28], and this 
work) suggests that this enzyme may not be required for the 
aggressive growth of these cells. Consequently, in these drug- 
sensitive cells PLD can not mediate the growth inhibitory effect 
of TAM. 
The development of multidrug resistance is accompanied, at 
least in MCF-7 cells, by increased expression of a relatively 
PtdEtn-specific PLD activity [28]. Considering that TAM can 
reverse MDRl-associated multidrug resistance [37], and that 
MCF-7/MDR cells are cross-resistant to TAM ([38], and refer- 
ences therein), the observed stimulatory effects of TAM on 
PLD activity are of considerable interest. Among other possi- 
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Fig. 3. Combined effects of serum and TAM on PtdEtn hydrolysis. MCF-7/MDR (A) and NIH 3T3 (B) cells were labeled with [~4C]ethanolamine 
followed by treatment of suspended cells with 2.5-50/zM concentrations of TAM for 20 rain in the absence ( ) or presence of2% serum (i) or 5% 
serum (-). Each point represents the mean + S.E.M. of six independent i cubations. Similar esults were obtained in another experiment performed 
in quadruplicate. 
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Fig. 4. Comparison of the effects of TAM and PMA on PtdEtOH 
formation. Attached MCF-7/WT (I), MCF-7/MDR (II) and NIH 3T3 
(III) cells, prelabeled with [~4C]palmitic acid, were incubated for 20 min 
in the absence (open bars) or presence of 25/tM TAM (hatched bars), 
100 nM PMA (cross-hatched bars), or TAM plus PMA (black bars). 
The ~4C content of PtdCho and PtdEtn in these cells was in the range 
of 512,000-876,000 and 149,000-226,000 dpm/106 cells, respectively. 
Data represent the mean _+ S.E.M. of six independent incubations. 
*Significantly (P < 0.01) different from the control (no addition) value 
(Student't t-test). 
bilities, these data suggest hat TAM might be able to modify 
multidrug resistance by stimulating its own efflux through 
mechanisms involving both the PLD system and P-glycopro- 
tein. In this regard, PtdEtn, the major substrate of PLD in 
MCF-7/MDR cells, has been shown to regulate the ATPase 
activity of P-glycoprotein [39]. It is also worth mentioning that 
reduced intratumoral ccumulation of TAM has been found in 
patients with locally recurrent breast cancer [40]. Further ex- 
periments are required to prove that the effects of TAM on 
PLD activity and multidrug resistance are indeed causally re- 
lated. 
Many patients who initially respond to TAM treatment expe- 
rience disease progression when taking TAM for an extended 
period of time. Several models have been developed, both in 
vitro and in vivo, to study the progression of breast cancer 
growth from the TAM-sensitive to the TAM-resistant stage. 
Because breast cancer is a highly heterogeneous disease, it is 
likely that multiple mechanisms will account for the TAM resis- 
tance. In this respect, it has recently been reported that while 
co-administration f TAM and the carcinogen 7,12-dimeth- 
ylbenzanthracene to rats resulted in a dramatic reduction in the 
number of tumors observed, a relatively large number of TAM- 
treated rats still developed tumors the growth of which was 
dependent on TAM [41]. One cannot exclude the possibility 
that the observed effects of TAM on the PLD system are, in 
fact, part of a complex mechanism ediating a growth stimula- 
tory, rather than a growth inhibitory, action of TAM. Another 
possibility is that stimulation of PLD by TAM increases the 
invasive capacity of resistant cells. In support of this possibility, 
Imamuka et al. [18] recently reported that bacterial PLD en- 
hanced invasiveness of rat ascites hepatoma (AH130) cells. 
Taking into account he significance of this issue, the above 
discussed possible actions of TAM will certainly require further 
consideration. 
Since MCF-7/MDR cells do not contain estrogen receptors 
[42,43], it is safe to conclude that the actions of TAM on the 
PLD system are not mediated by these receptors. Thus, it was 
less surprising to observe that TAM also stimulated PLD activ- 
ity in fibroblasts which are not known to possess significant 
levels of estrogen receptors. However, while the actions of 
TAM in MCF-7/MDR cells did not require serum, TAM failed 
to significantly stimulate the PLD activity in fibroblasts in the 
absence of serum. The reason for these differences is not 
known. 
It has been calculated that in treated patients the intratumor 
concentration of TAM can reach a level equivalent of 3.4-6.7 
#M [44]. Presently, it was found that, depending on the pres- 
ence of serum, 2.5-5/aM concentrations of TAM significantly 
stimulated PLD activity in MCF-7/MDR cells. Thus, it seems 
very likely that in the case of breast cancer, TAM-induced 
phospholipid hydrolysis represents a physiologically relevant 
process. In addition, the results howing that 5/IM TAM failed 
to induce significant PLD activation in fibroblasts suggests that 
drug resistant populations of breast cancer cells may be special 
targets for these actions of TAM. 
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